We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Simplifying Analytical Development for Viral Vector Production

Simplifying Analytical Development for Viral Vector Production content piece image

The number of viral vector-based gene therapies in clinical trials has recently grown into the thousands due to the tremendous genetic disease-curing potential they harbor. Yet the comprehensive characterization of critical quality attributes for the safety and efficacy of the material produced for these trials remains a challenge for both manufacturers and regulatory bodies alike. The demands on analytical development teams are oversized compared to legacy biopharmaceuticals and require a unique focus to address issues such as identification, characterization and enumeration of undesired by-products. Application of established regulatory guidance such as limits to residual host cell DNA requires additional scrutiny due to potential encapsidation and oncogenic potential.

Watch this webinar to discover:

  • An overview of common analytical assays employed in development and production of viral vector-based gene therapies
  • A review of regulatory guidance and concern around the safety of manufacturing impurities and by-products of common production systems
  • Detailed data on the implementation of robust, highly sensitive methods for residual DNA quantitation for both host cell and vector DNA in HEK293 and Sf9 systems
  • Introduction to a complete sample-to-results qPCR-based solution to simplify DNA fragment size testing targeting the E1a oncogene in HEK293 based production systems
Srinath Kashi Ranganath
Srinath Kashi Ranganath
Staff Scientist, Field Applications